President Donald Trump said on Tuesday he is developing a plan that will encourage competition in the drug industry and bring down prices for medicines, as the House of Representatives leadership unveiled a new health care plan.
We spend a lot of time highlighting sectors and industries that are outperforming the broader market and garnering plenty of bullish headlines, but it's just as important to identify lagging market niches for long-only investors to avoid and short-oriented traders to target.
The pharmaceutical industry's middlemen face a 2017 clampdown.

Drugmaker Shire said on Tuesday it was seeking to buy Baxalta, a company spun-off by Baxter International last month, for $30 billion to forge the leading global specialist in rare diseases.